Next Article in Journal
Fabrication of a Low-Cost Microfluidic Device for High-Throughput Drug Testing on Static and Dynamic Cancer Spheroid Culture Models
Next Article in Special Issue
The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer
Previous Article in Journal
Use of Autotransfusion following Percutaneous Thrombectomy for Cardiogenic Shock Due to Pulmonary Embolism in a Single Session—A Case Report
Previous Article in Special Issue
Challenges in Diagnosis of Uretero–Arterial Fistulas after Complex Pelvic Oncological Procedures—Single Center Experience and Review of the Literature
 
 
Article
Peer-Review Record

Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer

Diagnostics 2023, 13(8), 1393; https://doi.org/10.3390/diagnostics13081393
by Xinxin Li 1,†, Lili Li 2,†, Xi Xiong 3, Qihui Kuang 1, Min Peng 4, Kai Zhu 5,* and Pengcheng Luo 1,*
Reviewer 1:
Diagnostics 2023, 13(8), 1393; https://doi.org/10.3390/diagnostics13081393
Submission received: 6 March 2023 / Revised: 22 March 2023 / Accepted: 7 April 2023 / Published: 11 April 2023
(This article belongs to the Special Issue Biomarkers for Detection and Prognosis in Urologic Oncology)

Round 1

Reviewer 1 Report

In this study, the correlation between the CBX family and BLCA patient prognosis was investigated to analyze CBX6 and CBX7 as putative prognostic markers. Data were taken mostly by platforms online available such as  ONCOMINE, The Cancer Genome Atlas database, and Proteinatlas. This means that the initial statements made are based on data sets from others. However, finally, the main results were partly confirmed by expression analysis of one normal urethral cells (SV-HUC-1) in contrast to two cancer cell lines (5637 and T24) by western blotting and immunohistological analysis.

Major issues

-          2.11. Cell lines: Have the cell lines been authenticated and tested for mycoplasma?

-          2.12. Western blotting: How much soluble protein (µg) was loaded on the gels? Which kind of gels were used? How the loading control and the internal standards were performed? Which secondary antibody was used?

-          2.13. Multiple immunohistochemistry: From where the tissue sections were received? Which antibodies were used and from where they were purchased? Ethics vote?

-          3.4. Prognostic value of CBXs in BLCA patients: CBX1 and CBX3 seem to have a greater influence on the overall survival.

-          Figure 11. How many technical and biological replicates were analyzed by western blotting? Please add to the figure legend.

-          The discussion should not be a repetition of the results section. A critical discussion with the current literature and data is desirable.

Minor issues:

-          British or American English: make it consistent.

-          Line 41: 50 - 70 years old (Spaces before and after the hyphen)

 

-          Line 84: f BLCA. and provide (point or comma?)

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Major comments:

1. how do the authors explain the difference in CBX expression between deiffrent UC cell lines? 

2. The authors need to present the expression of all CBX family, not just CBX6 and CBX 7

3. the survival data is only deflected in a univariate kaplan meier analysis - the authors need to perform a multivariate cox analysis including all known clinical prognostic and histopathological factors for UC patients and assess whether q-values (not just p-values) from TCGA data are actually significant. 

Author Response

Please see the attachment.

 

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

All issues have been addresed.

Reviewer 2 Report

The authors have successfully addressed most of the Reviewers' comments. No additional concerns at this point.

Back to TopTop